What Edwards Lifesciences's 8-K filings say: 5 filings, latest Nov 4, 2026
Edwards Lifesciences filed its latest 8-K with the SEC on Nov 4, 2026. It discusses international growth and product launch.
Public (EW)Medical Equipment Manufacturing10,000+ employeesedwards.comLinkedIn
Get Edwards Lifesciences' live signals in Claude or ChatGPT, or by API
What changed at Edwards Lifesciences this week? Use Autobound signals for edwards.com.- Filed
- Nov 4, 2026
- Filings
- 5
- Signals
- 12
Source: Autobound Signal API · 68 signals tracked for Edwards Lifesciences · updated
8-K · latest 8
What Edwards Lifesciences's 8-K filings say
- SEC EDGAR
8-K
Filed · 2 signals
FDA Approves PASCAL Precision for Tricuspid and PASCAL Ace with Capture Clarity
Edwards Lifesciences received U.S. FDA approval for the PASCAL Precision system for tricuspid regurgitation and PASCAL Ace with Capture Clarity for degenerative mitral TEER procedures, initiating measured rollouts.
Capture Clarity
TAVR and SAPIEN 3 Ultra RESILIA Expand in Japan and Europe
Outside the U.S., Edwards saw strong SAPIEN adoption in Europe supported by updated ESC and EACTS guidelines, and secured dedicated reimbursement for SAPIEN 3 Ultra RESILIA in Japan.
- SEC EDGAR
8-K
Filed · 3 signals
The incoming leader will likely review all strategic initiatives, partnerships, and technology investments during the 2027 transition period.
The planned retirement of the Corporate VP of Strategy and Corporate Development initiates a leadership transition and a search for a successor.
- SEC EDGAR
8-K
Filed · 1 signal
Edwards Lifesciences adds 7M shares to its long-term employee stock incentive program.
The company is significantly expanding its equity compensation pool, indicating a strategic focus on attracting and retaining key talent to drive future growth.
- SEC EDGAR
8-K
Filed · 3 signals
$8M
new CFO initial RSU grant value
- SEC EDGAR
8-K
Filed · 3 signals
FTC obtains court injunction to block proposed acquisition of JenaValve Technology, Inc.
A U.S. District Court has blocked the company's planned acquisition of JenaValve, derailing a key strategic initiative.
JenaValve Technology, Inc
Edwards Lifesciences' acquisition of JenaValve Technology blocked by FTC injunction on Jan 9, 2026
A federal court injunction has blocked the company's planned acquisition of JenaValve, forcing an immediate and significant change to its strategic growth plans.
JenaValve Technology, Inc
Showing 8 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Edwards Lifesciences with the Signal API
One POST /v1/companies/enrich call with edwards.com returns Edwards Lifesciences 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"edwards.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about Edwards Lifesciences 8-K
When did Edwards Lifesciences file its latest 8-K?
What did Edwards Lifesciences disclose in its latest 8-K?
Where can I read Edwards Lifesciences's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .